CTIC CTI BioPharma Corp.

0  -0%
Previous Close 0.65
Open 0.65
Price To Book 0.93
Market Cap 37,686,171
Shares 57,978,725
Volume 179,599
Short Ratio
Av. Daily Volume 293,277

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released July 9. 2018. Primary endpoint not met.
PIXUVRI - PIX306 Trial
B-cell non-Hodgkin lymphoma
Phase 2 data to be presented 3Q 2019 with Phase 3 trial to commence also in 3Q 2019 with data due mid-2021.
Pacritinib - PAC203
Phase 3 trial potentially in the pipeline.
Older patients with AML or high-risk myelodysplastic syndrome (MDS) - cancer
Phase 3 - noted July 2016 that unlikely to have survival benefit
Ovarian cancer

Latest News

  1. CTI BioPharma Reports Second Quarter 2019 Financial Results
  2. CTI BioPharma Announces Outcome From End-of-Phase-2a Meeting With U.S. Food and Drug Administration (FDA) Regarding Pacritinib for Treatment of Myelofibrosis
  3. CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Thursday, Jun. 20
  4. CTI BioPharma to Present at the Jefferies Global Healthcare Conference on Wednesday, Jun. 5
  5. CTI BioPharma: 1Q Earnings Snapshot
  6. CTI BioPharma Reports First Quarter 2019 Financial Results
  7. CTI BioPharma to Present at the 18th Annual Needham Healthcare Conference on Wednesday, Apr. 10
  8. CTI BioPharma Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights
  9. CTI BioPharma to Present at Oppenheimer's 29th Annual Healthcare Conference on Tuesday, Mar. 19
  10. CTI BioPharma ups CEO pay as stock hovers near record low
  11. CTI BioPharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference Wednesday, Feb. 27
  12. CTI BioPharma collects $10M payment for former chemotherapy drug
  13. CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®
  14. Ex-CTI BioPharma CEO seeks startup funds as yacht lawsuit dismissed
  15. CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update
  16. CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib
  17. CTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib Development
  18. As CTI BioPharma restructures, former CEO James Bianco launches startup
  19. The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch